Document Detail


Cisplatin induced cell killing and chromosomal aberrations in CHO cells: treated during G1 or S phase.
MedLine Citation:
PMID:  7678144     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Variation in sensitivity to cisplatin during the cell cycle was studied in synchronous CHO cells treated during G1 or late S phase. The cells were assayed for cell killing, cell-cycle delay, and chromosomal aberrations after they were treated with cisplatin (1-12 micrograms/ml) for 1 h at 37 degrees C. They were either plated for colony survival, or colcemid was added from 12 to 40 h after plating followed by fixation 4 h later for analysis of chromosomal aberrations after the cells completed 1 or 2 cycles (i.e. first or second mitosis). Cells treated with 6 micrograms/ml exhibited about a 10-h delay during the first cycle after treatment during G1 compared with about 3 h during the first cycle and 6 h during the second cycle after treatment during late S. In both cases, cells entering metaphase exhibited predominantly chromatid-type breaks and exchanges. For both cell killing and chromosomal aberrations, the cells in G1 were 1.5-1.6 times more sensitive than those treated in late S, with 1 aberration per cell corresponding to about 37% survival. However, the exchanges and breaks were observed primarily in the first mitosis when cells were treated in G1 compared with the second mitosis when cells were treated in late S. These results suggest that DNA replication opposite cisplatin cross-links in the DNA results in lethal chromosomal aberrations.
Authors:
G Krishnaswamy; W C Dewey
Related Documents :
7174744 - The role of protein metabolism in glucocorticoid-induced prolongation of g1 phase in hu...
16386904 - Anticancer activity of a series of platinum complexes integrating demethylcantharidin w...
22445214 - Quantitative analyses of the behavior of exogenously added bacteria during an aciduloco...
9645434 - Alteration of the largest subunit of rna polymerase ii and its effect on chromosome sta...
12051814 - Membrane-bound neuregulin1 type iii actively promotes schwann cell differentiation of m...
20384214 - Biomaterials in cell microencapsulation.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Mutation research     Volume:  293     ISSN:  0027-5107     ISO Abbreviation:  Mutat. Res.     Publication Date:  1993 Jan 
Date Detail:
Created Date:  1993-02-01     Completed Date:  1993-02-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0400763     Medline TA:  Mutat Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  161-72     Citation Subset:  IM    
Affiliation:
Radiation Oncology Research Laboratory, University of California, San Francisco 94143.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
CHO Cells
Cell Cycle* / drug effects
Cell Death / drug effects*
Chromosome Aberrations*
Cisplatin / administration & dosage,  toxicity*
Cricetinae
Drug Administration Schedule
Mitosis / drug effects
Polyploidy
S Phase
Sister Chromatid Exchange
Grant Support
ID/Acronym/Agency:
CA 02915/CA/NCI NIH HHS; CA 31813/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of excision repair genes in non-malignant bone marrow from cancer patients.
Next Document:  Activated murine neutrophils induce unscheduled DNA synthesis in B lymphocytes.